Editorial Commentary
Tunnel vision: seeking to reduce peritubular leakage after lung resection
AME Clinical Trials Review
2023;
1:
18
.
(25 December 2023)
Editorial Commentary
The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer
AME Clinical Trials Review
2023;
1:
17
.
(25 December 2023)
Editorial Commentary
EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges
AME Clinical Trials Review
2023;
1:
16
.
(25 December 2023)
Editorial Commentary
Improving patient selection through tumor genomic recharacterization to overcome resistance to targeted therapy: commentary on the final analysis of the INSIGHT trial
AME Clinical Trials Review
2023;
1:
15
.
(25 December 2023)
Editorial Commentary
The importance of long-term safety, tolerability, and health-related quality of life: lessons from the ADAURA trial
AME Clinical Trials Review
2023;
1:
14
.
(25 December 2023)
Editorial Commentary
Pafolacianine for imaging of pulmonary neoplasms: a promising supplement for modern surgical technique
AME Clinical Trials Review
2023;
1:
13
.
(25 December 2023)
Editorial Commentary
Encorafenib and binimetinib as a new regimen for BRAF mutant non-small cell lung cancer
AME Clinical Trials Review
2023;
1:
12
.
(25 December 2023)
Editorial
A tale of two lung-sparing surgeries: the rise of segmentectomy and wedge resection in stage IA non-small-cell lung cancer
AME Clinical Trials Review
2023;
1:
11
.
(25 December 2023)
Editorial Commentary
Overall survival of ADAURA: game, set, and match?
AME Clinical Trials Review
2023;
1:
10
.
(25 October 2023)
Editorial Commentary
What is the role of consolidation immunotherapy after chemoradiotherapy in stage III EGFR-mutant non-small cell lung cancer?
AME Clinical Trials Review
2023;
1:
9
.
(25 October 2023)
Editorial Commentary
Segmentectomy for partially solid non-small cell lung cancer: what counts—the resection or the patient?
AME Clinical Trials Review
2023;
1:
8
.
(25 October 2023)
Editorial Commentary
Real world data are needed to establish safety of adjuvant immune checkpoint inhibitors after pneumonectomy
AME Clinical Trials Review
2023;
1:
7
.
(25 October 2023)
Editorial Commentary
Neoadjuvant immunotherapy for resectable non-small cell lung cancer—what lies ahead
AME Clinical Trials Review
2023;
1:
6
.
(25 October 2023)
Editorial Commentary
Towards better outcomes: segmentectomy for ground-glass opacity-dominant non-small cell lung cancer 3 cm or less—insights from JCOG1211
AME Clinical Trials Review
2023;
1:
5
.
(25 October 2023)
Editorial Commentary
The immune “tsunami” has arrived at the shores of early-stage non-small cell lung cancer
AME Clinical Trials Review
2023;
1:
4
.
(25 October 2023)
Editorial Commentary
An ever-stronger case for circulating tumor DNA monitoring in ALK+ lung cancer
AME Clinical Trials Review
2023;
1:
3
.
(25 October 2023)
Editorial Commentary
Editorial commentary: the importance of staging hasn’t changed, but the procedure of choice has
AME Clinical Trials Review
2023;
1:
2
.
(25 October 2023)
Editorial
Advancing the understanding, reflection, and translation of clinical trials: inaugural editorial to AME Clinical Trials Review
AME Clinical Trials Review
2023;
1:
1
.
(25 October 2023)